The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials
Abstract
PURPOSE: To examine the responsiveness of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) by using data from the MARINA and ANCHOR trials in neovascular age-related macular degeneration (AMD) and to establish the change in the NEI VFQ-25 associated with a 15-letter change in best corrected visual acuity (BCVA). METHODS: In MARINA, 716 patients were randomized to monthly intravitreal ranibizumab (0.3 or 0.5 mg) or sham injections. In ANCHOR, 423 patients were randomized to monthly ranibizumab (0.3 or 0.5 mg) with sham photodynamic therapy (PDT) or sham ocular injections with verteporfin PDT. Patients had follow-up interviews and BCVA measurements over 24 months. Data were analyzed separately for MARINA and ANCHOR, and treatment groups were pooled within each trial. The clinically relevant difference in NEI VFQ-25 was estimated based on regression models of change from baseline to month 12 in BCVA. RESULTS: Subgroups categorized by BCVA change (>or=15 letters gained, <15 letters lost or gained, or >or=15 letters lost) differed substantially in mean change in NEI VFQ-25 composite scores and three pre-specified subscale scores (near activities, distance activities, and vision-specific dependency) over 12 months. According to the regression models, the difference associated with a 15-letter change was 4 to 6 points for the composite score and the three pre-specified subscales. CONCLUSIONS: These data support the use of the NEI VFQ-25 as a responsive and sensitive measure of vision-related function in neovascular AMD populations. Based on MARINA and ANCHOR data, a 4- to 6-point change in NEI VFQ-25 scores represents a clinically meaningful change corresponding to a 15-letter change in BCVA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At week 96, the score increase from baseline was clinically relevant in the following subscales: mental health (þ15.8points), dependency (þ7.8 points), and role difficulties (þ7.7 points).25”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [25]
Citations
Cites
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 5×
“measured at 2 m at each visit and at 4 m at day 0, month 12, and month 24.(24) NEI VFQ-25 Methods”
BackgroundResultInfluentialPrevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Measuring change over time: Assessing the usefulness of evaluative instruments
Guyatt, G., Walter, S., & Norman, G. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90069-5 · Cited by 1,880
Prevalence of Open-Angle Glaucoma Among Adults in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.532 · Cited by 1,110
Klaver, C. C. W. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.5.653 · Cited by 881
Psychometric Properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ)
Mangione, C. M. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.11.1496 · Cited by 848
Age-related macular degeneration
de Jong, P. T. V. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062326 · Cited by 787
Cited by
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Wall, M., McDermott, M. P., Kieburtz, K. D., Corbett, J. J., Feldon, S. E., Friedman, D. I., Katz, D. M., Keltner, J. L., Schron, E. B., & Kupersmith, M. J. (2014) · JAMA · doi:10.1001/jama.2014.3312 · Cited by 550
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Kempen, J. H., Altaweel, M. M., Holbrook, J. T., Jabs, D. A., Louis, T. A., Sugar, E. A., & Thorne, J. E. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.07.027 · Cited by 334
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 271
Metadata
- Authors
- Sun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M.
- Affiliations
- From the Retina Associates of Florida, Tampa, Florida;
- University of Hawaiʻi at Mānoa (US)
- Genentech (US)
- Johns Hopkins University (US)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2009-08-01
- Volume
- 50
- Issue
- 8
- Pages
- 3629
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2158029475
- Cited by
- 170
- References
- 32
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 11 · 2023: 9 · 2022: 13 · 2021: 11 · 2020: 19 · 2019: 9 · 2018: 3 · 2017: 17 · 2016: 7 · 2015: 6 · 2014: 15 · 2013: 14 · 2012: 3
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- NEI VFQ-25, visual function questionnaire, neovascular age-related macular degeneration, visual acuity change, questionnaire responsiveness, ranibizumab, MARINA trial, ANCHOR trial
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, National Institutes of Health (U.S.), Surveys and Questionnaires, Sensitivity and Specificity, United States, Visual Acuity, Vitreous Body, Sickness Impact Profile, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials. https://app.cochat.ai/papers/10.1167/iovs.08-3225
- The paper
- Sun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M. (2009). Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.08-3225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.